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expression of SLAM signaling factors characterizes
sarcoidosis remission: a 4-year longitudinal study
Katarina Osolnik, Matija Rijavec and Peter Korosec*Abstract
Background: Invariant NKT (iNKT) cells are regulatory lymphocytes that may be important in disorders with
increased Th1 responses. We utilized a 4-year longitudinal observational study of iNKT cells and SLAM signaling
pathway factors, which are important for iNKT development in patients with newly diagnosed sarcoidosis.
Methods: Detailed clinical, functional, and radiographic evaluation and determination of iNKT peripheral blood cell
counts and expression of SLAM signaling factors was carried out at presentation and after 3 months, 1 year, and
4 years of disease follow-up in 29 patients with pulmonary sarcoidosis. At presentation, we also evaluated the
frequencies of pulmonary BALF iNKT cells. We also included 37 control subjects.
Results: We demonstrated a marked deficiency of blood and lung iNKT cells and decreased expression of SLAM
signaling factors in patients with newly diagnosed sarcoidosis. During 4 years of disease follow-up, there was a
significant increase in blood iNKT cell numbers and in expression of SLAM signaling factors, mainly SLAMF1, SLAMF6,
and FYN. This increase clearly correlated with improvement in patients’ clinical symptoms. At the 4-year endpoint,
the disease had gone into remission in the great majority of patients and thus also iNKT cell deficiency. Moreover,
at the 4-year endpoint iNKT level reached the iNKT level of the control subjects.
Conclusions: Our longitudinal study showed that a disposal of iNKT deficiency in parallel with an increase in
expression of SLAM signaling factors characterizes the clinical remission of sarcoidosis.Introduction
In contrast to both conventional T lymphocytes and other
types of Tregs, invariant natural killer T (iNKT) cells com-
prise a unique subgroup of immunoregulatory T lympho-
cytes that are restricted by the non-classical MHC class I
molecule CD1d and expression of the invariant Vα24–Jα18
T cell receptor (TCR) preferably paired with Vβ11 [1-6].
Furthermore, iNKT cells can either upregulate or downreg-
ulate cell-mediated immunity and thus these cells could
have diverse influences in various disease models [5-8].
Sarcoidosis is the most common interstitial lung disease
in the western world. It frequently involves organs other
than the lungs. This multisystem disorder features the
presence of CD4+ T cells that differentiate into Th1-like
cells and amplify the local immune response [9-11]. Des-
pite much research over the past decade, the cause of the* Correspondence: peter.korosec@klinika-golnik.si
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unless otherwise stated.Th1-biased hyperactive response remains unknown. Ho
et al. [12] first hypothesized that the loss of immunoregu-
lation by iNKT cells could explain amplified and persistent
T cell activity. This hypothesis was based on NOD mice
that are deficient for iNKT cells. These mice are generally
healthy, but they are predisposed to disorders with in-
creased Th1 responses [13]. Ho reported a significant de-
crease in iNKT cell frequency in the peripheral blood and
BALF of sarcoidosis patients. We recently confirmed the
deficiency of iNKT cells in BALF of corticosteroid-naive
sarcoidosis patients [14]. Nevertheless, these association
studies examined only one sample from each patient and,
despite the fact that the iNKT cell defect was evident at
some disease stages, there are currently no data about the
nature of this defect or whether iNKT cells could be im-
portant for the long-term course of the disease. A more
definitive study would have to closely follow the progress
of iNKT cells over a longer period. Another question that
arises is whether the iNKT cell defect is also affected byLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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dependent on signaling via the SLAM family of surface re-
ceptors [5,15-17]. For this reason, we followed up blood
iNKT cells and expression of SLAM signaling factors to-
gether with detailed clinical data in 29 patients with newly
diagnosed pulmonary sarcoidosis over 4 prospective years.
Methods
Study subjects
Twenty-nine patients (mean age 38 years; range 25–74
years; 14 women, Caucasians) with newly diagnosed, histo-
logically confirmed pulmonary sarcoidosis were recruited
in a prospective manner from the Golnik University Clinic
and first examined at diagnosis and then compared at
3 months, 1 year, and 4 years (mean after 4.2 years; range
3.5–4.6 years). Five subjects had Löfgren syndrome
(Table 1). For iNKT and SLAM analysis, four patients were
missing at 3 months and five at 1 year (Figure 1). We also
included 28 healthy control subjects (mean age 39 years;Table 1 Results of chest radiographic stages, serum
angiotensin–converting enzyme (sACE), lung function





Stage I, n (%) 8 (28)
Stage II, n (%) 19 (66)
Stage III, n (%) 2 (7)
Lung function
% predicted FEV1 92 (43–114)
% FVC 94 (51–118)
% DLCO 92 (46–122)
sACE (μkat/L) ** 1.0 (0.1–4.4)
Organ involved†
Lung involvement, n (%) 29 (100)
Multisystem, n (%) 16 (55)
Erythema nodosum, n (%) 5 (17)
(Löfgren syndrome, n (%)) 5 (17)†
Skin, n (%) 6 (21)
Liver, n (%) 3 (10)
Lymphatic glands, n (%) 2 (6)
Parotid glands and spleen, n (%) 1 (3)
Lung function and sACE data are presented as medians with the range.
*Standard radiographic staging consists of five stages: Stage 0 = normal, Stage
I = bilateral hilar lymphadenopy, Stage II = BHL and parenchymal infiltration,
Stage III = radioparenchymal infiltration without BHL, and Stage IV =
irreversible fibrosis with loss of lung volume.
**sACE was determined by the kinetic method. Our normal values for sACE
are 0.33–1.17 μkat/l. Sixteen (52%) patients had higher-than-normal
concentrations of sACE.
†All patients with erythema nodosum included those fulfilling the criteria of
Löfgren syndrome (plus bilateral hilar adenopathy and arthralgia).range 20–62 years; 15 women); 15 control subjects were
paired-sampled in a 3-month interval. The analysis involv-
ing BAL included an additional nine control subjects with-
out any pulmonary morbidity (mean age 47 years; range
27–84 years; five women) and normal lung function tests.
Some of these bronchoalveolar lavage (BAL) controls have
already been published [14]. All subjects gave their written
consent and the study was approved by the Slovenian
National Medical Ethics Committee.
Chest radiographs, functional and clinical data
Pulmonary disease was evaluated at presentation and at the
follow-up by chest radiography and pulmonary function
testing in order to determine the disease course. FEV1,
FVC, and DLCO were used to assess the presence of lung
function impairment. All patients were also assessed for
extrapulmonary disease and serum angiotensin-converting
enzyme (sACE; Table 1).
Bronchoalveolar lavage
BAL differential cell count and BAL TBNK immunopheno-
typing were performed at diagnosis, as previously described
[14,18]. In brief: we instilled seven aliquots of 20 ml and
one of 10 ml, up to a total volume of 150 ml of saline. After
each instillation, the aliquot was immediately recovered,
pooled, and thereafter processed for cytological and flow
cytometry analysis. Cytospin preparations were stained ac-
cording to the May–Grünwald–Giemsa and Papanicolaou
methods and differential cell count was performed by
counting 200 cells.
For TBNK immunophenotyping, the BALF was strained
through a 70 mm cell strainer (BD Biosciences), centrifuged
and resuspended in Haemaccel (Behringwerke, Marburg,
Germany), and incubated with the respective mAbs (CD3,
CD4, CD8, CD14, CD19, CD45, CD16/56, BD Biosciences,
San Jose, CA, USA) for 15 min, followed by lysing, washing,Figure 1 The number of patients included with sarcoidosis at
each longitudinal time point for cellular iNKT and SLAM
expression analysis.
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and SimulSET software (BD Biosciences).iNKT cells
Invariant NKT (CD3 + Vα24-Jα18 + Vβ11+) were identi-
fied by using mAb against CD3, Vα24-Jα18 (clone 6B11)
T cell receptor (TCR; all from BD Biosciences), and
Vβ11 TCR (Immunotech, Marseille, France) [14,18]. Ab-
solute iNKT counts were performed in combination with
routine TruCOUNT tubes and TriTEST CD3/CD4/
CD45 staining (all from BD Biosciences).
The frequencies of BALF iNKT cells were established at
diagnosis and the cells were prepared alongside cells for
TBNK immunophenotyping. First, the BALF cells were in-
cubated with the respective iNKT mAbs for 15 min,
followed by lysing, washing, and fixation, and then ana-
lyzed using FACSCalibur and CellQuest software (BD Bio-
sciences). The BALF iNKT cells in patients were expressed
as % of BALF T lymphocytes and were also compared
with frequencies of BALF iNKT cells in control subjects.
Invariant NKT cells in peripheral blood were first ex-
amined at diagnosis and then compared at 3 months,
1 year, and 4 years for each patient. They were also com-
pared with control subjects. Whole blood with EDTA anti-
coagulant was first incubated with iNKT mAbs for
15 min, followed by lysing, washing, and fixation, and ana-
lyzed using FACSCalibur and CellQuest software (BD Bio-
sciences). The frequencies of blood iNKT cells were
expressed as % of blood T lymphocytes. The parallel blood
sample for absolute count was incubated with standard-
ized TriTEST CD3/CD4/CD45 mAbs in TruCOUNT
tubes followed by lysing and analyzing of T lymphocyte
absolute numbers by FACSCalibur and MultiSET software
(BD Biosciences). The absolute number of iNKT cells in
whole blood was calculated by multiplying the frequencies
of blood iNKT cells expressed as the proportion of blood
T lymphocytes with the absolute number of blood T lym-
phocytes, and this was expressed as the number of iNKT
cells per μl of whole blood.SLAM signaling factors gene expression
Whole blood was collected in PAXgene Blood RNA Tubes
(PreAnalytiX GmbH, Hombrechtikon, Switzerland) at diag-
nosis and then at 3 months, 1 year, and 4 years for each pa-
tient and also in control subjects and stored at −30°C until
further processing. Total RNA was isolated from blood
samples using the PAXgene Blood RNA Kit (PreAnalytiX
GmbH) and quantified by a Qubit fluorometer using the
Quant-iT™ RNA Assay Kit (Invitrogen Corporation, Carls-
bad, CA, USA) according to the manufacturer’s instruc-
tions. A reverse transcription reaction was performed using
a High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, USA).Real-time PCR was performed on an ABI PRISM 7500
Real-Time PCR System (Sequence Detection System in-
strument equipped with SDS version 1.3.0 software; Ap-
plied Biosystems).
The human GAPD (GAPDH) Endogenous Control
(Applied Biosystems) with the MGB probe labeled with
FAM at the 5′ end was used for normalization of the
target genes. Primers and probes for the genes of interest
(SLAMF1, SLAMF6, FYN, and SLAM adaptor protein
(SAP) (SH2D1A)) were also supplied by Applied Biosys-
tems as TaqMan® Gene Expression Assays with the MGB
probes labeled with FAM at the 5′ end (the assay IDs are
Hs00158978_m1, Hs00941607_m1, Hs00234150_m1, and
Hs00372941_m1, respectively). PCR reactions were set up in
separate tubes withTaqMan Universal PCR Master Mix (Ap-
plied Biosystems) at default thermal conditions. All measure-
ments were performed in triplicate for each time point and
relative expression was analyzed using the ΔΔCt method.
Statistical analysis
Data distribution was evaluated using the D’Agostino–
Pearson test. Because the majority of data were not
normally distributed, we performed a Wilcoxon or
Mann–Whitney test. A chi-square test was used on bi-
nominal data. Data were expressed as median and range, if
not otherwise specified. Probability values of P < 0.05 were
accepted as significant. Analyses were performed using
GraphPad Prism (GraphPad Software, La Jolla, CA, USA).
Results
Monitoring of pulmonary and extrapulmonary disease
and treatment
At diagnosis, nine patients showed chest radiographic
stage I, 19 showed stage II, and two showed stage III
(Table 1). At 3 months, the stages were highly comparable.
However, after 1 year there was a significant improvement
in radiographic chest stages (six showed stage 0), and even
more after 4 years, when 17 patients showed stage 0, two
stage I, nine stage II, and one stage III (Figure 2A). The
pulmonary function data also significantly improved, with
a median increase of predicted FEV1 from 92 to 97%, FVC
from 94 to 103%, and DLCO from 92 to 100% after 4 years
of disease follow-up (Figure 2B–D). There was also a sig-
nificant decrease of sACE (from 1 to 0.6 μkat/l; Figure 2E)
after 4 years of disease follow-up.
At presentation, 16 patients showed extrapulmonary
disease (Table 1). At follow-up there was a decrease to 12
patients at 3 months, to eight at 1 year, and finally after
4 years to six patients (four with skin involvement and
two with liver involvement) (Figure 2F).
Among the 29 patients, only five needed initial treat-
ment with oral corticosteroids. At 1 year only one patient
remained on treatment; later, in the 3rd year, the disease
again progressed in another patient, and so finally after
Figure 2 Radiographic, functional, clinical, and treatment data in newly diagnosed patients with sarcoidosis and then over 4 years of
disease follow-up: (A) chest radiographic stages, (B, C, D) lung functions, (E) serum ACE levels, (F) manifestations of granuloma in organs
other than the lungs, and (G) systemic corticosteroid treatment. The data measured are presented with the median and interquartile range.
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needed corticosteroid treatment (Figure 2G).
Monitoring of iNKT cells
The frequencies of BALF iNKT cells were determined only
at the diagnosis and they were compared with the BALF
of control subjects. The median (range) BALF iNKT cell
frequency was 0.11% (0–2.55), whereas in controls the
iNKT frequencies were about 10 times higher (0.96%; 0.2–
2.51; Figure 3A). The accompanying analysis of BALF cell
counts and TBNK immunophenotyping are presented in
Table 2. BALF of sarcoidosis patients showed a higher
lymphocyte total cell count and CD4/CD8 T ratio with
higher CD4 and lower CD8 T lymphocyte subset frequen-
cies, but comparable CD3 T and B lymphocyte, NK cell,
and nonbiased NKT cell frequencies.
In peripheral blood, iNKT cells were closely monitored
from the diagnosis of sarcoidosis over 4 prospective years.
These data were also compared with iNKT cells in control
subjects; in some of the controls iNKT cells were also
monitored over 3 months. The median (range) frequency
of blood iNKT cells at diagnosis was 0.12% (0.02–0.58), at
3 months 0.15% (0.01–0.76), at 1 year 0.15% (0.02–0.79),
and after 4 years 0.21% (0.01–1.3) (Figure 3B). The median
(range) absolute numbers of blood iNKT cells at diagnosisFigure 3 Frequencies (A) of BALF iNKT (CD3+ Vα24-Jα18-Vβ11) cells in
BALF of the control subjects; Frequencies (B) and absolute counts of
disease follow-up and in comparison to the healthy control subjects.were 0.94 cells/μl (0.12–7.47), at 3 months 1.16 cells/μl
(0.00–10.11), at 1 year 1.45 cells/μl (0.26–11.2), and after
4 years 1.87 cells/μl (0.14–15.7; Figure 3C). Thus after
4 years iNKT cell frequencies and absolute count signifi-
cantly increased, and became comparable with control
subjects (0.2%; 0.03–1.4 and 2.29 cells/μl; 0.41–12.3). Rep-
resentative dot plots of iNKT cell analysis over 4 years of
disease follow-up show a sarcoidosis patient with disease
remission (Figure 4A) and a sarcoidosis patient with
chronic disease (Figure 4B).
Monitoring of blood iNKT cells in 15 controls at the 3-
month interval showed no differences, either in frequencies
(0.25% (0.03–1.44) vs. 0.20% (0.03–1.42)) or in absolute
counts (4.7 cells/μl (0.41–12.3) vs. 5 cells/μl (0.44–12.30)).
Similarly, when we followed the frequencies and absolute
count of blood T lymphocytes in sarcoidosis patients, we
did not find any significant differences (at diagnosis vs.
4 years: 67% (39–86) vs. 70% (42–89) and 860 cells/μl
(479–1832) vs. 1019 cells/μl (311–2416)).
Monitoring the expression of SLAM signaling factors
The expression of SLAM signaling factors SLAMF1,
SLAMF6, FYN, and SAP was monitored in patients’ whole
blood at the same time points as iNKT cells. SLAMF1 ex-
pression remained similarly low after 3 months and 1 yearnewly diagnosed sarcoidosis patients and in comparison to
iNKT cells in whole blood (C) of the same patients over 4 years of
Data are presented with the median and interquartile range.
Table 2 Bronchoalveolar lavage fluid (BALF) cell counts and T lymphocytes, B lymphocytes, NK, and NKT-like cells in
BALF from patients with sarcoidosis sampled upon diagnosis and control subjects
BALF cell counts Sarcoidosis (N = 29) Controls (N = 9) p value
Total cells (×105 cells/ml) 1.2 (0.5–3.2) 1.00 (0.4–2.2) n.s.
Neutrophils (%) 3 (1–6) 2 (1–22) n.s.
Eosinophils (%) 1 (1–4) 1 (1–2) n.s.
Macrophages (%) 68 (24–93) 87 (69–95) 0.003
Lymphocytes (%) 29 (6–76) 9 (3–14) 0.0005
% of lymphocytes
T lymphocytes (CD3+) 89 (61–97) 86 (60–97) n.s.
T helper (CD3+CD4+) 73 (37–90) 53 (27–80) 0.008
T cytotoxic (CD3+CD8+) 11 (4–39) 23 (13–57) 0.002
B lymphocytes (CD19+) 0 (0–3) 0 (0–2) n.s.
NK cells (CD3−CD16/56+) 2 (1–32) 2 (0–4) n.s.
nonbiased NKT cells (CD3+CD16/56+) 3.5 (1–11) 3 (2–5) n.s.
CD4/CD8 ratio 7.29 (1–22.5) 2.2 (0.5–6.2) 0.002
Data are presented as medians with the range.
n.s. = non significant.
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creased and became comparable with the level in control
subjects (Figure 5A). SLAMF6 expression demonstrated a
moderate increase through 3 months and significantly
through 1 to 4 years of follow-up, and it was already com-
parable to controls after 1 year (Figure 5B). A very similar
significant increase was also shown for FYN expression
(Figure 5C). SAP expression varied through 3 months and
1 year of disease follow-up, and after 4 years it remained
at the same level as at diagnosis and still lower than in
control subjects (Figure 5D).
Discussion
This study confirmed a marked blood and lung deficiency
of invariant NKT cells in newly diagnosed patients withFigure 4 Representative flow cytometry dot plots of iNKT cell analyze
with disease remission and (B) in a sarcoidosis patient with chronic dpulmonary sarcoidosis. It also showed that this deficiency
is associated with decreased expression of the SLAM sig-
naling factors that are important for development of these
immunoregulatory T cells. Next, we closely followed the
progress of blood iNKT cells and the expression of SLAM
factors in sarcoidosis patients over a 4-year period. During
longitudinal disease follow-up, there was a significant and
gradual increase in iNKT cell numbers and expression of
SLAM signaling factors. This increase correlated with im-
provement in patients’ overall radiographic, functional,
and clinical symptoms, and finally at the 4-year endpoint
the disease had gone into remission in the great majority
of patients and thus also iNKT cell deficiency.
A causative association between iNKT cells and Th1-
biased disorders such as sarcoidosis is based on thes over 4 years of disease follow-up (A) in a sarcoidosis patient
isease.
Figure 5 Relative expression levels of genes (A) SLAMF1, (B) SLAMF6, (C) FYN, and (D) SAP in whole blood of patients with sarcoidosis over
4 years of disease follow-up and in comparison to healthy control subjects. Data are presented with the median and interquartile range.
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related immunoregulatory role. The most direct evidence
for this hypothesis comes from animal models, such as
NOD mice with lower iNKT cell numbers, which are char-
acterized by a Th1-biased hyperactive response, and in
which the adoptive transfer of iNKT cells has been shown
to prevent the development of Th1-biased disorders
[19-22]. Unfortunately, in the case of sarcoidosis, no reliable
animal model is available; therefore only clinical analyses of
iNKT cells can be studied. One of the key questions that
arose with the first evidence of iNKT cell deficiency in sar-
coidosis [12,14] was whether the peripheral blood defi-
ciency reflects the systemic state or is simply a
consequence of iNKT compartmentalization; that is, the
lack of blood iNKT cells might be due to sequestration of
these cells in the compartments of disease activity. It seems
that compartmentalization is very unlikely because the defi-
ciency of blood iNKTcells was clearly evident alongside the
iNKT deficiency in airways [12, 14, and current report] as
well as in the sarcoid mediastinal lymph nodes [23] and in
granulomatous lesions of cutaneous sarcoidosis [24]. In
contrast, only one report demonstrated increased Vα24
TCR expression by RT-PCR in the lymph nodes of sarcoid-
osis patients in comparison to the lymph nodes of lung-cancer patients [25]. Nevertheless, this observation was not
confirmed by methodologically more stringent cellular ap-
proaches, which was the case for other reports [12,14,24].
In contrast to previous studies [12,14,24], this study
benefited from long-term longitudinal sampling and de-
tailed patient follow-up. Importantly, we closely followed
the longitudinal progress of blood iNKT cells and showed
that the increase in iNKT cells clearly correlated with pa-
tients’ clinical improvement. Moreover, after 4 years, when
the disease resolved in the great majority of patients, blood
iNKT levels reached the iNKT levels of the control sub-
jects. Unfortunately, BAL sampling was carried out only at
diagnosis and, because the disease was mostly resolved
after 4 years, it did not seem ethical to perform another
bronchoscopy and thus obtain a paired pulmonary sample.
The observations that the restoration of iNKT cells could
contribute to disease resolution also support the idea of
possible therapeutic targeting of iNKT cells. Namely, clin-
ical trials have shown that administering iNKT cell mito-
gens is well tolerated by patients and this can result in
the expansion of residual iNKT cell populations [26]. In
addition, this study did not show any differences concern-
ing the nonbiased CD3 +CD16/56+ NKT cells in sarcoid-
osis patients, which is similar to previous reports [14,18].
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coidosis. In particular, iNKT cell development is highly
dependent on SLAM signaling factors. SLAMF1 and its
homologue SLAMF6 are type 1 plasma membranes and,
in response to ligation, Src tyrosine kinase FYN is re-
cruited to SAP [27]. In NOD mice a defect in SLAMF1
expression is responsible for the lower iNKT cell num-
bers [28]. Furthermore, mice lacking SAP completely
lack iNKT cells, yet conventional T cells are present in
normal numbers. In patients with X-linked lymphopro-
liferative disease (defect in the SH2D1A gene, which en-
codes the SAP molecule) development of iNKT cell is
also absent [17]. However, a significant difference be-
tween human and mouse iNKT cells development is re-
lated to their place of maturation. In mice, mature iNKT
cells develop in the thymus. In contrast, the equivalent de-
velopment steps in humans are not completed in the thy-
mus, but are completed in the periphery—or, at least,
mature NKT cells are extremely rare in the human thymus,
in contrast to their frequency in blood [29,30]. Due to the
importance of the periphery for iNKT development in
humans, it was reasonable to monitor the expression of
SLAM signaling factors in the periphery of sarcoidosis pa-
tients. We showed that their expression upon disease pres-
entation was much lower than in the control subjects,
suggesting that impaired iNKT development might be the
cause for the iNKT cell deficiency. Furthermore, during the
course of the disease the expression of SLAMF1, SLAMF6,
and FYN factors increased significantly, and this increase
correlated with the increase in the iNKT cell numbers and
the clinical remission of the disease.
The limitation of expression analysis was that SLAM
family receptors are also expressed on T cells, B cells,
and dendritic cells and SLAM adaptor protein (SAP) on
T and NK cells [31]. However, only development of
iNKT cells, but not other hematopoietic cells, is absent
in patients with X-linked lymphoproliferative disease
(SAP defect) [17] and SAP-deficient mice [16,17] or re-
duced in NOD [19-22], SLAMF1/SLAMF6 double mu-
tant chimeras [27] and in Fyn deficient mice [32,33].
Because of that specific SLAM cellular development
effect we believe that the measurement and quantitative
follow-up of SLAM expression in whole blood sample is
specific enough for their association with iNKT cells
and also a possible reason for iNKT cell deficiency.
The heterogeneity among patients with sarcoidosis is
well known [9]. However, the majority of patients with sar-
coidosis have a remission within 5 years after diagnosis,
with few or no consequences [9-11]. Furthermore, a recur-
rence after 1 or more years of remission is uncommon
and affects less than 5% of patients, despite the fact that
recurrent disease may develop at any age and in any organ
[10,11]. Conversely, up to one-third of patients show
unrelenting chronic disease that can lead to clinicallysignificant organ impairment [10,11]. The incidence of
chronic disease varies throughout the world, with the high-
est peak and severity in black Americans [10]. In our study,
only two patients seem to have had chronic disease, and in
all other patients the remission was clearly evident within
4 years. Furthermore, only five patients needed corticoster-
oid treatment up to the 1st year, and after 1 year only one
chronic patient remained continually on treatment and an-
other started again in the 3rd year. Löfgren syndrome—an
acute presentation consisting of arthralgia, erythema
nodosum, and bilateral hilar adenopathy—was exhibited
in five patients. Obviously, our study group represents
patients with pulmonary sarcoidosis that have a good
prognosis. Therefore, the iNKT cellular and SLAM ex-
pression results and implication should be predisposing
only for patients with such a reversible clinical pheno-
type. We also did not separately analyze chronic or
Löfgren syndrome patients because those subgroups
were too small.Conclusion
In conclusion, we showed that the deficiency of iNKT cells
and decreased expression of SLAM signaling factors con-
stitute a significant immunoregulatory T cell abnormality
in sarcoidosis, and further that the longitudinal increase in
iNKT cell numbers and the changes in expression of
SLAM signaling factors characterize the clinical remission
of sarcoidosis. These observations support the hypothesis
that the loss of immunoregulatory iNKT cells might con-
tribute to the clinical appearance of sarcoidosis and, vice
versa, that recovery of immunoregulatory iNKT cells
might contribute to an improvement in symptoms and
thus to the clinical remission of sarcoidosis. Because most
of the data were based on analysis of patients that had a
reversible clinical phenotype and in whom remission oc-
curred within 4 years, further prospective studies on iNKT
cells should obviously focus on patients with unrelenting
chronic disease that leads to clinically significant organ
impairment. Furthermore, further studies are also needed
to better understand the mechanistic and possible Th1-
related role of iNKT cells in sarcoidosis. Only such data
could confirm the biological and functional importance of
this specific population of immunoregulatory T cells in
immunopathogenesis of sarcoidosis.Abbreviations
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